We are live on ! Find out more
TCM

Tang Capital Management Portfolio holdings

AUM $1.97B
1-Year Est. Return 125.1%
This Fund
S&P 500
This Quarter Est. Return
+16.47%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$1.4B
AUM Growth
+$418M
Cap. Flow
+$336M
Cap. Flow %
23.99%
Top 10 Hldgs %
35.88%
Holding
162
New
35
Increased
43
Reduced
14
Closed
8

Top Buys

Rank Stock Value
1
ITOS
iTeos Therapeutics
ITOS
+$36.7M
2
CRBP icon
Corbus Pharmaceuticals
CRBP
+$30.7M
3
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$27.6M
4
RLAY icon
Relay Therapeutics
RLAY
+$26.7M
5
IMCR icon
Immunocore
IMCR
+$25.5M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$24.4M
2
DVAX
Dynavax Technologies
DVAX
+$6.61M
3
BEAM icon
Beam Therapeutics
BEAM
+$2.58M
4
CRSP icon
CRISPR Therapeutics
CRSP
+$2.54M
5
INBX icon
Inhibrx
INBX
+$2.37M

Sector Composition

Rank Sector Weight
1 Healthcare 95.59%
2 Technology 1.47%
3 Communication Services 1.22%
4 Real Estate 0.34%
5 Financials 0.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XOM icon
126
ExxonMobil
XOM
$634B
$821K 0.06%
7,004
+5,096
+267% +$588K
JNJ icon
127
Johnson & Johnson
JNJ
$625B
$813K 0.06%
+5,015
New +$799K
VSTM icon
128
Verastem
VSTM
$610M
$807K 0.06%
270,000
-271,514
-50% -$737K
LAB icon
129
Standard BioTools
LAB
$314M
$787K 0.06%
+407,755
New +$799K
PFE icon
130
Pfizer
PFE
$153B
$745K 0.05%
+25,738
New +$751K
MGNX icon
131
MacroGenics
MGNX
$257M
$720K 0.05%
218,856
– –
ATRA icon
132
Atara Biotherapeutics
ATRA
$76.1M
$611K 0.04%
75,196
– –
PBYI icon
133
Puma Biotechnology
PBYI
$454M
$510K 0.04%
200,000
– –
AFMD
134
DELISTED
Affimed
AFMD
$498K 0.04%
+148,315
New +$654K
PGEN icon
135
Precigen
PGEN
$2.59B
$474K 0.03%
+500,000
New +$631K
EGRX
136
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$443K 0.03%
118,857
– –
IVVD icon
137
Invivyd
IVVD
$218M
$337K 0.02%
330,172
+130,172
+65% +$141K
AMLX icon
138
Amylyx Pharmaceuticals
AMLX
$2.54B
$324K 0.02%
100,000
– –
NFLX icon
139
Netflix
NFLX
$309B
$303K 0.02%
4,270
– –
AXP icon
140
American Express
AXP
$230B
$271K 0.02%
1,001
– –
LONA
141
LeonaBio Inc
LONA
$72.1M
$268K 0.02%
60,000
-45,272
-43% -$1.06M
GE icon
142
GE Aerospace
GE
$384B
$261K 0.02%
1,383
– –
ALL icon
143
Allstate
ALL
$67.5B
$239K 0.02%
1,260
– –
SHW icon
144
Sherwin-Williams
SHW
$89.8B
$234K 0.02%
+612
New +$214K
TMUS icon
145
T-Mobile US
TMUS
$190B
$221K 0.02%
+1,071
New +$205K
UAL icon
146
United Airlines
UAL
$42.1B
$221K 0.02%
+3,872
New +$179K
AMZN icon
147
Amazon
AMZN
$2.96T
$217K 0.02%
1,164
– –
CLX icon
148
Clorox
CLX
$12.7B
$201K 0.01%
+1,236
New +$183K
MCRB icon
149
Seres Therapeutics
MCRB
$48.9M
$189K 0.01%
10,000
-110,356
-92% -$2.24M
RLMD icon
150
Relmada Therapeutics
RLMD
$527M
$165K 0.01%
50,825
-187,049
-79% -$606K
3 4 5
6
7

Similar funds

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return

Tang Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Tang Capital Management held 162 positions worth $1.4B, up 43% from $982M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Tang Capital Management deployed $336M of net new capital in Q3 2024, opening 35 new positions and adding to 43 existing holdings. Its largest new stake was iTeos Therapeutics: 2,407,800 shares worth $24.6M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Dynavax Technologies, an estimated $6.61M trimmed.

  • Tang Capital Management's largest Q3 2024 buy was iTeos Therapeutics: 2,407,800 shares worth $24.6M.
  • Tang Capital Management added most to Aurinia Pharmaceuticals in Q3 2024, an estimated $27.6M increase.
  • Tang Capital Management's biggest Q3 2024 reduction was Dynavax Technologies, cutting an estimated $6.61M.
  • Tang Capital Management fully exited Eli Lilly in Q3 2024, selling an estimated $24.4M.
  • Tang Capital Management's ten largest holdings make up 36% of its $1.4B portfolio in Q3 2024.
  • Tang Capital Management opened 35 new positions and closed 8 in Q3 2024.
  • Tang Capital Management's portfolio value rose 43% quarter-over-quarter to $1.4B.

Based on Tang Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.